Feasibility of a Collaborative, Prospective Interdisciplinary Review and Pharmacy-Based Dispensing Process for...

Current evidence shows that vitamin K antagonist reversal requires either prothrombin complex concentrate or fresh frozen plasma. Prior research has shown that FFP requires longer preparation times and may not correct INR as quickly. However, no prior work had resolved whether a collaborative pharmacy-based dispensing model could improve PCC4 use. This gap motivated a study to compare reversal processes. Existing knowledge lacked data on real-world effectiveness of PCC4 in urgent settings. No prior work had resolved the impact of interdisciplinary review on administration speed. This paper contributes by analyzing a new workflow. The study's design addresses a practical gap in emergency anticoagulation reversal. It builds on prior work but introduces a novel pharmacy integration.

The aim was to evaluate a new collaborative process for PCC4 administration in warfarin reversal. The specific problem was the need for faster and more effective reversal in urgent clinical scenarios. This study sought to compare PCC4 and FFP in a real-world setting. The motivation came from observed delays in FFP preparation and administration. The study aimed to assess whether interdisciplinary review improved outcomes. It also sought to measure INR correction rates and adverse event frequencies. The goal was to determine if PCC4 could be safely and effectively integrated into clinical practice. The study focused on time metrics and safety outcomes.

The study used a retrospective before-and-after cohort design at a single center. Researchers analyzed 98 patients requiring urgent warfarin reversal. Data collection included timing metrics and INR measurements. The primary endpoint was time from order to administration. Secondary endpoints included infusion duration and INR correction rates. Patients were divided into two groups: FFP and PCC4 recipients. Adverse events were tracked for both groups. Statistical analysis compared median times and correction rates between groups.

Median administration time for PCC4 was 44 minutes versus 69 minutes for FFP (P = 0.015). Infusion time for PCC4 was 54 minutes compared to 151 minutes for FFP (P < 0.0001). INR correction to ≤1.4 occurred in 72% of PCC4 patients versus 28% of FFP patients (P < 0.0001). Adverse events occurred in 4% of both groups. These findings suggest faster PCC4 administration and better INR correction. The study also found similar safety profiles between the two agents. These results were consistent across the study period. The data support the effectiveness of the new dispensing model.

The authors propose that PCC4, when used with collaborative review and pharmacy dispensing, offers faster administration. They suggest that this process improves INR correction rates compared to FFP. The study found similar adverse event rates between the two agents. These findings support the use of PCC4 in urgent reversal scenarios. The authors state that the new workflow is feasible in clinical practice. They suggest that the model could improve emergency anticoagulation management. The study does not claim that PCC4 is superior in all aspects. The authors emphasize the importance of interdisciplinary collaboration.